D&D Pharmatech Inc. (KOSDAQ:347850)
South Korea
· Delayed Price · Currency is KRW
77,500
-1,200 (-1.52%)
Apr 29, 2026, 3:30 PM KST
D&D Pharmatech Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 3,394,821 | 3,996,552 | 513,608 | - | - | - | |
| Market Cap Growth | 596.83% | 678.13% | - | - | - | - | |
| Enterprise Value | 3,367,668 | 3,964,719 | 494,061 | - | - | - | |
| Last Close Price | 77500.00 | 91800.00 | 12150.00 | - | - | - | |
| PS Ratio | 789.93 | 929.95 | 44.91 | - | - | - | |
| PB Ratio | 42.98 | 50.60 | 7.38 | - | - | - | |
| P/TBV Ratio | 69.08 | 81.33 | 14.45 | - | - | - | |
| EV/Sales Ratio | - | 922.54 | 43.20 | - | - | - | |
| Debt / Equity Ratio | 0.08 | 0.08 | 0.14 | 0.15 | 1.47 | 0.32 | |
| Net Debt / Equity Ratio | -0.34 | -0.34 | -0.29 | -0.14 | 0.09 | -0.23 | |
| Net Debt / EBITDA Ratio | 0.94 | 0.94 | 1.04 | 0.83 | -0.03 | 0.51 | |
| Net Debt / FCF Ratio | 1.26 | 1.26 | 0.91 | 0.82 | -0.03 | 0.61 | |
| Asset Turnover | 0.04 | 0.04 | 0.13 | 0.22 | 0.00 | 0.01 | |
| Quick Ratio | 6.43 | 6.43 | 3.20 | 2.28 | 0.47 | 1.14 | |
| Current Ratio | 9.41 | 9.41 | 3.58 | 2.61 | 0.61 | 1.22 | |
| Return on Equity (ROE) | -32.29% | -32.29% | -47.25% | 9.29% | -174.72% | -43.71% | |
| Return on Assets (ROA) | -21.79% | -21.79% | -17.70% | -9.75% | -24.89% | -19.70% | |
| Return on Invested Capital (ROIC) | -70.93% | -66.86% | -51.56% | -30.26% | -108.81% | -65.13% | |
| Return on Capital Employed (ROCE) | -36.90% | -36.90% | -29.00% | -18.80% | -177.30% | -41.10% | |
| Earnings Yield | -0.69% | -0.59% | -5.57% | - | - | - | |
| FCF Yield | -0.62% | -0.53% | -4.32% | - | - | - | |
| Buyback Yield / Dilution | -6.21% | -6.21% | -8.05% | -16.38% | 2.05% | -12.66% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.